Second- or Third-Line Recurrent or Metastatic Cervical Cancer research hub

C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

This study is testing a new drug (Tisotumab Vedotin) for cervical cancer that has come back or spread, and hasn't responded to previous treatments. It compares whether the new drug works better than standard chemotherapy to help people live longer.